Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation with postponed donor lymphocyte infusion in elderly acute myeloid leukemia and high risk myelodysplasia patients

Trial Profile

Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation with postponed donor lymphocyte infusion in elderly acute myeloid leukemia and high risk myelodysplasia patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Amsacrine (Primary) ; Cytarabine (Primary) ; Fludarabine (Primary) ; Alemtuzumab; Antithymocyte globulin; T cell replacement therapy
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FLAMSA-TCD-NMA-AlloSCT
  • Most Recent Events

    • 01 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top